Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research1,190

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research1,190

FiltersClear all

Status

Recruiting350
Not yet recruiting11
Enrolling by invitation17
Active, not recruiting322
Completed358
Terminated132

Study type

Interventional1,190
Observational101
Expanded access19
Not on ClinicalTrials.gov1,519

Phase

Phase 3325
Not applicable304
Phase 2286
Phase 1103
Phase 1/277
Phase 454

Investigator

Gail J Roboz41
Manish A Shah27
Parag Goyal23
Sonal Kumar23
Scott T. Tagawa22

Show all 50Show fewer

Department

Medicine750
Pediatrics81
Neurology46
Psychiatry46
Obstetrics and Gynecology41

Show all 22Show fewer

Condition

Leukemia, Myeloid, Acute50
Prostatic Neoplasms49
Breast Neoplasms41
Heart Failure31
Neoplasms31

Show all 50

Intervention type

Drug788
Other176
Device166
Biological150
Procedure119
Behavioral83

Sponsor type

Industry685
WCM (investigator-initiated)230
Other academic173
NIH76
Cooperative group25
Unknown1

Start date

Has results posted342

Interventional×Clear all

Showing 1061–1080 of 1,190 studiesSort:

CompletedInterventional · Phase 3NCT05096403 ↗
A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)
Maria Teresa DeSanchoPI
Intervention
Drug: Pegcetacoplan · Drug: Placebo matching Pegcetacoplan
Dates
Oct 2022 – May 2024

FiltersClear all

Status

Recruiting350
Not yet recruiting11
Enrolling by invitation17
Active, not recruiting322
Completed358
Terminated132

Study type

Interventional1,190
Observational101
Expanded access19
Not on ClinicalTrials.gov1,519

Phase

Phase 3325
Not applicable304
Phase 2286
Phase 1103
Phase 1/277
Phase 454

Investigator

Gail J Roboz41
Manish A Shah27
Parag Goyal23
Sonal Kumar23
Scott T. Tagawa22

Show all 50Show fewer

Department

Medicine750
Pediatrics81
Neurology46
Psychiatry46
Obstetrics and Gynecology41

Show all 22Show fewer

Condition

Leukemia, Myeloid, Acute50
Prostatic Neoplasms49
Breast Neoplasms41
Heart Failure31
Neoplasms31

Show all 50

Intervention type

Drug788
Other176
Device166
Biological150
Procedure119
Behavioral83

Sponsor type

Industry685
WCM (investigator-initiated)230
Other academic173
NIH76
Cooperative group25
Unknown1

Start date

Has results posted342

Interventional×Clear all

Showing 1061–1080 of 1,190 studiesSort:

CompletedInterventional · Phase 3NCT05096403 ↗
A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)
Maria Teresa DeSanchoPI
Intervention
Drug: Pegcetacoplan · Drug: Placebo matching Pegcetacoplan
Dates
Oct 2022 – May 2024

Phase 2/3

Early phase 13

Harini Sarva21
Ashish Saxena20
Cora Sternberg20
Ellen K. Ritchie18
Ruben Niesvizky16
Dana Jeremy Lukin14
Evelyn M. Horn14
Pinkal Desai14
Ellen J Scherl13
Daniel W Skupski12
Eleni Andreopoulou12
Jim W. Cheung12
Jia Ruan12
Massimo Cristofanilli12
Sujit Sheth12
Catherine Butkus Small11
James E. Ip11
John Allan11
Anna C Pavlick10
Alexander Ja-Ho Chou10
Aliza B Solomon10
Alpana P. Shukla10
Marshall J. Glesby10
Anna Podolanczuk9
Barbara Ma9
Catherine McGuinn9
Silvia Chiara Formenti9
Hani Lamie Ashamalla9
Kristen Marks9
Robert J. Kaner9
Shari Lipner9
Maria Teresa DeSancho8
Samuel Kim8
Andrew F. Alexis7
Erin Mulvey7
Evelyn Cantillo7
Jean W. Pape7
Sebastian A. Mayer7
Brian DeRubertis6
Conor Liston6
Darshana M Dadhania6
David M Nanus6
Joseph M Scandura6
Lok W. Yung6
Mehraneh Dorna Jafari6

Neurological Surgery19

Cardiothoracic Surgery17

Urology15

Rehabilitation Medicine13

Population Health Sciences9

Otolaryngology Head and Neck Surgery7

Pathology and Laboratory Medicine1

Pharmacology1

Show fewer

Carcinoma, Non-Small-Cell Lung27
Multiple Myeloma27
Colitis, Ulcerative26
Crohn Disease26
Myelodysplastic Syndromes26
Recurrence25
Atrial Fibrillation23
Neoplasm Metastasis23
Obesity23
Parkinson Disease21
COVID-1920
Colorectal Neoplasms18
Depression18
Cardiovascular Diseases17
Hematologic Neoplasms17
HIV Infections16
Non-alcoholic Fatty Liver Disease15
Overweight15
Melanoma13
Idiopathic Pulmonary Fibrosis12
Inflammatory Bowel Diseases12
Leukemia, Lymphocytic, Chronic, B-Cell12
Lung Neoplasms12
Lymphoma, Non-Hodgkin12
Primary Myelofibrosis12
Hypertension11
Myeloproliferative Disorders11
Alzheimer Disease10
Coronary Artery Disease10
Hypertension, Pulmonary10
Leukemia, Myelomonocytic, Chronic10
Stroke10
Urinary Bladder Neoplasms10
Cognitive Dysfunction9
Leukemia9
Lung Diseases, Interstitial9
Pulmonary Arterial Hypertension9
Burkitt Lymphoma8
Carcinoma, Renal Cell8
Chronic Pain8
Fibrosis8
Lymphoma, Follicular8
Lymphoma, Large B-Cell, Diffuse8
Adenocarcinoma Of Esophagus7
Anemia7

Radiation

Diagnostic test22

Dietary supplement14

Combination product11

Genetic6

· Results posted

Sponsor

Swedish Orphan Biovitrum AB

Cold Agglutinin Disease

CompletedInterventional · Phase 3NCT05101187 ↗

Phase III, Adjudicator-blinded, Randomised Study to Evaluate Efficacy and Safety of Treatment With Olorofim Versus Treatment With AmBisome® Followed by Standard of Care in Patients With Invasive Fungal Disease Caused by Aspergillus Species

Markus PlatePI

Intervention: Drug: Olorofim · Drug: AmBisome®
Dates: Apr 2022 – Nov 2025
Sponsor: F2G Ltd

Invasive Aspergillosis

TerminatedInterventional · Phase 1NCT05121103 ↗

A Phase 1/1b, Open-label Multi-center Two-part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma

Ruben NiesvizkyPI

Intervention: Drug: EZM0414
Dates: May 2022 – Apr 2024· Results posted
Sponsor: Epizyme

Multiple Myeloma, RefractoryDiffuse Large B-Cell LymphomaDiffuse Large B Cell Lymphoma Refractory+1 more

CompletedInterventional · Phase 2NCT05130970 ↗

A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Garadacimab in Subjects With Idiopathic Pulmonary Fibrosis

Robert J. KanerPI

Intervention: Drug: Garadacimab · Drug: Placebo
Dates: Feb 2022 – Jan 2024· Results posted
Sponsor: CSL Behring GmbH

Idiopathic Pulmonary Fibrosis

CompletedInterventional · Not applicableNCT05136092 ↗

A Pilot Study to Determine Fructose Uptake by Primary Human Colorectal Tumors

Mehraneh Dorna JafariPI

Intervention: Dietary supplement: Cohort 1: HFCS (fructose) fed · Dietary supplement: Cohort 2: D-Xylose (xylose-fed)
Dates: Feb 2022 – Aug 2024
Sponsor: Weill Medical College of Cornell University

Colorectal Tumors

CompletedInterventional · Phase 3NCT05142774 ↗

An Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream, 1% in Subjects With Atopic Dermatitis

Andrew F. AlexisPI

Intervention: Drug: Tapinarof cream, 1%
Dates: Oct 2021 – Feb 2024· Results posted
Sponsor: Dermavant Sciences, Inc.

Atopic Dermatitis

CompletedInterventional · Not applicableNCT05143255 ↗

Developing a Communication Intervention to Help People With Memory Challenges and Their Care Partners Engage in Advance Care Planning

Sara CzajaPI

Intervention: Behavioral: KNOW
Dates: Dec 2024 – Feb 2026
Sponsor: Weill Medical College of Cornell University

Alzheimer DiseaseDementia

CompletedInterventional · Phase 2NCT05147805 ↗

A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

Evelyn M. HornPI

Intervention: Drug: Treprostinil Palmitil · Drug: Placebo
Dates: Aug 2022 – Mar 2025
Sponsor: Insmed, Inc.

Pulmonary Arterial Hypertension

TerminatedInterventional · Phase 3NCT05153499 ↗

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of the Efficacy, Safety, and Tolerability of a Single Oral Administration of CP101 for the Prevention of Recurrent Clostridioides Difficile Infection (CDI)

Carl V. CrawfordPI

Intervention: Biological: CP101 · Other: Placebo
Dates: Nov 2021 – Feb 2023· Results posted
Sponsor: Finch Research and Development LLC

Recurrent C. Difficile Infection

TerminatedInterventional · Phase 3NCT05171075 ↗

A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab vs. Dalteparin on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With GI/GU Associated VTE

Maria Teresa DeSanchoPI

Intervention: Biological: Abelacimab · Drug: Dalteparin
Dates: Sep 2022 – Apr 2026
Sponsor: Anthos Therapeutics

Venous ThromboembolismDeep Venous ThrombosisPulmonary Embolism

CompletedInterventional · Phase 3NCT05171855 ↗

A Multicenter, Open-Label, Extension Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

Georgiana Alina DobriPI

Intervention: Drug: Lonapegsomatropin
Dates: Dec 2021 – Dec 2024· Results posted
Sponsor: Ascendis Pharma Endocrinology Division A/S

Adult Growth Hormone DeficiencyEndocrine System DiseasesHormone Deficiency

CompletedInterventional · Phase 2NCT05176951 ↗

A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

Evelyn M. HornPI

Intervention: Drug: Treprostinil Palmitil · Drug: Placebo
Dates: Dec 2022 – Mar 2024
Sponsor: Insmed, Inc.

Pulmonary Hypertension

TerminatedInterventional · Phase 3NCT05179057 ↗

Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, With Cross-Over, of Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation

Tsiporah B ShorePI

Intervention: Drug: Posoleucel · Drug: Placebo
Dates: Apr 2022 – Jan 2024· Results posted
Sponsor: AlloVir, Inc.

Adenovirus Infection

TerminatedInterventional · Phase 3NCT05181540 ↗

A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)

Tsiporah B ShorePI

Intervention: Biological: AB-205 · Other: Placebo
Dates: Feb 2022 – Dec 2023
Sponsor: Angiocrine Bioscience, Inc.

Hodgkin LymphomaNon Hodgkin Lymphoma

CompletedInterventional · Phase 2NCT05183204 ↗

A Phase 2 Trial of Paxalisib Combined With a Ketogenic Diet and Metformin for Newly Diagnosed and Recurrent Glioblastoma

Howard Alan FinePI

Intervention: Drug: Paxalisib · Drug: Metformin · Other: Ketogenic Diet
Dates: Feb 2022 – Aug 2026
Sponsor: Weill Medical College of Cornell University

Glioblastoma

CompletedInterventional · Not applicableNCT05184985 ↗

Efficacy of TrueRelief as a Non-Pharmacological Alternative for Pain Relief in Supraspinatus Tendonitis

Vandana SoodPI

Intervention: Device: TrueRelief device · Device: Sham TrueRelief device
Dates: May 2022 – Jun 2023 (est.)
Sponsor: Weill Medical College of Cornell University

Supraspinatus TendinitisShoulder Pain

CompletedInterventional · Phase 1NCT05195918 ↗

Dose Ranging Study of Oral Epigallocatechin-3-gallate (EGCG) Given Daily for 12 Weeks to Patients With Idiopathic Pulmonary Fibrosis (IPF) Evaluating Safety, PK Interactions With Standard of Care Drugs, and Biomarkers of Drug Effect

Anna PodolanczukPI

Intervention: Combination product: EGCG 300 mg + Nintedanib · Combination product: EGCG 300 mg + Pirfenidone · Combination product: Placebo 2 capsules + Nintedanib or Pirfenidone · Combination product: EGCG 600 mg + Nintedanib · Combination product: EGCG 600 mg + Pirfenidone · Combination product: Placebo 4 capsules + Nintedanib or Pirfenidone
Dates: Aug 2023 – Mar 2026
Sponsor: University of California, San Francisco

Idiopathic Pulmonary Fibrosis

TerminatedInterventional · Phase 1/2NCT05198843 ↗

Phase Ib/II Study of EPA-Based EphA2 Targeted Therapy for Patients With Metastatic Triple-Negative Inflammatory Breast Cancer

Massimo CristofanilliPI

Intervention: Drug: Dasatinib · Dietary supplement: Icosapent Ethyl
Dates: Nov 2022 – Dec 2023· Results posted
Sponsor: National Cancer Institute

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Inflammatory Carcinoma

CompletedInterventional · Not applicableNCT05201495 ↗

A Clinical Evaluation of the Jewel P-WCD in Subjects at High Risk for Sudden Cardiac Arrest

Gioia TurittoPI

Intervention: Device: Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)
Dates: Jan 2022 – Nov 2023· Results posted
Sponsor: Element Science, Inc.

Sudden Cardiac Arrest

CompletedInterventional · Not applicableNCT05217420 ↗

Moving Well Intervention for Patients Preparing to Undergo Total Knee Arthroplasty (TKA)

Iris Y Navarro MillanPI

Intervention: Behavioral: Moving Well · Behavioral: Staying Well
Dates: Apr 2022 – Jan 2025
Sponsor: Weill Medical College of Cornell University

Osteoarthritis, Knee

‹ Prev 1 2 3 4 5…53 54 55 56 57 58 59 60 Next ›